The firm shows a Beta (market volatility) of 3.82, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biostem Technologies will likely underperform. At this point, Biostem Technologies has a negative expected return of -0.0646%. Please make sure to confirm Biostem Technologies' maximum drawdown, as well as the relationship between the accumulation distribution and day typical price , to decide if Biostem Technologies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak
Strong
Over the last 90 days Biostem Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, Biostem Technologies is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow
140.7 K
Free Cash Flow
-581.6 K
Biostem
Biostem Technologies Relative Risk vs. Return Landscape
If you would invest 504.00 in Biostem Technologies on September 21, 2025 and sell it today you would lose (80.00) from holding Biostem Technologies or give up 15.87% of portfolio value over 90 days. Biostem Technologies is currently does not generate positive expected returns and assumes 6.5686% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of otc stocks are less volatile than Biostem, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
Expected Return
Risk
Given the investment horizon of 90 days Biostem Technologies is expected to under-perform the market. In addition to that, the company is 9.25 times more volatile than its market benchmark. It trades about -0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.09 per unit of volatility.
Biostem Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biostem Technologies' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Biostem Technologies, and traders can use it to determine the average amount a Biostem Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0098
Best Portfolio
Best Equity
Good Returns
Average Returns
Small Returns
Cash
Small Risk
Average Risk
High Risk
Huge Risk
Negative Returns
BSEM
Based on monthly moving average Biostem Technologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biostem Technologies by adding Biostem Technologies to a well-diversified portfolio.
Biostem Technologies Fundamentals Growth
Biostem OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Biostem Technologies, and Biostem Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biostem OTC Stock performance.
By examining Biostem Technologies' fundamental ratios, stakeholders can obtain critical insights into Biostem Technologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Biostem Technologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida. Biostem Technologies is traded on OTC Exchange in the United States.
Things to note about Biostem Technologies performance evaluation
Checking the ongoing alerts about Biostem Technologies for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Biostem Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Biostem Technologies generated a negative expected return over the last 90 days
Biostem Technologies currently holds 1.32 M in liabilities. Biostem Technologies has a current ratio of 0.25, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biostem Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Biostem Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostem Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostem to invest in growth at high rates of return. When we think about Biostem Technologies' use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 2.52 M. Net Loss for the year was (2.39 M) with profit before overhead, payroll, taxes, and interest of 163.78 K.
Biostem Technologies currently holds about 1.37 M in cash with (581.57 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12.
Evaluating Biostem Technologies' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Biostem Technologies' otc stock performance include:
Analyzing Biostem Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biostem Technologies' stock is overvalued or undervalued compared to its peers.
Examining Biostem Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
Evaluating Biostem Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biostem Technologies' management team can help you assess the OTC Stock's leadership.
Pay attention to analyst opinions and ratings of Biostem Technologies' otc stock. These opinions can provide insight into Biostem Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Biostem Technologies' otc stock performance is not an exact science, and many factors can impact Biostem Technologies' otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
Other Information on Investing in Biostem OTC Stock
Biostem Technologies financial ratios help investors to determine whether Biostem OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostem with respect to the benefits of owning Biostem Technologies security.